BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38032349)

  • 21. Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA.
    Teuber A; Schulz T; Fletcher BS; Gontla R; Mühlenberg T; Zischinsky ML; Niggenaber J; Weisner J; Kleinbölting SB; Lategahn J; Sievers S; Müller MP; Bauer S; Rauh D
    Nat Commun; 2024 Jan; 15(1):63. PubMed ID: 38167404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous
    Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P
    Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
    Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK
    Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations.
    Pantaleo MA; Lolli C; Nannini M; Astolfi A; Indio V; Saponara M; Urbini M; La Rovere S; Gill A; Goldstein D; Ceccarelli C; Santini D; Rossi G; Fiorentino M; Di Scioscio V; Fusaroli P; Mandrioli A; Gatto L; Catena F; Basso U; Ercolani G; Pinna AD; Biasco G
    Genet Med; 2015 May; 17(5):391-5. PubMed ID: 25188872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
    Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avapritinib: First Approval.
    Dhillon S
    Drugs; 2020 Mar; 80(4):433-439. PubMed ID: 32100250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
    Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
    J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Status and clinical analysis of c-kit and PDGFRA mutations in the gastrointestinal stromal tumors].
    Du CY; Shi YQ; Zhou Y; Fu H; Zhao GF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):371-5. PubMed ID: 18636362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy.
    Corti C; Conforti F; Pala L; Catania C; Cocorocchio E; Ferrucci PF; Curigliano G; Queirolo P; de Pas T
    Eur J Cancer; 2022 Sep; 172():332-339. PubMed ID: 35820244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
    Miettinen M; Lasota J
    Arch Pathol Lab Med; 2006 Oct; 130(10):1466-78. PubMed ID: 17090188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
    Bombac A; Zakotnik B; Bucic M; Setrajcic Dragos V; Gazic B; Stegel V; Klancar G; Novakovic S
    Int J Oncol; 2020 Jun; 56(6):1468-1478. PubMed ID: 32236636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
    He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
    Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.
    Patel SR; Reichardt P
    Cancer; 2021 Jul; 127(13):2187-2195. PubMed ID: 33974733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
    Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
    Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.